While Cardiff Oncology Inc has overperformed by 1.47%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CRDF fell by -4.84%, with highs and lows ranging from $5.64 to $2.01, whereas the simple moving average jumped by 22.43% in the last 200 days.
On July 08, 2025, Ladenburg Thalmann started tracking Cardiff Oncology Inc (NASDAQ: CRDF) recommending Buy. A report published by Jefferies on June 24, 2025, Initiated its previous ‘Hold’ rating for CRDF. Craig Hallum also rated CRDF shares as ‘Buy’, setting a target price of $8 on the company’s shares in an initiating report dated September 06, 2024. Robert W. Baird initiated its ‘Outperform’ rating for CRDF, as published in its report on December 08, 2021. Maxim Group’s report from August 09, 2021 suggests a price prediction of $20 for CRDF shares, giving the stock a ‘Buy’ rating. H.C. Wainwright also rated the stock as ‘Buy’.
Analysis of Cardiff Oncology Inc (CRDF)
Further, the quarter-over-quarter decrease in sales is -46.83%, showing a negative trend in the upcoming months.
Cardiff Oncology Inc’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. The goal here is to ensure that your current return on equity of -74.15% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 6.22, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and CRDF is registering an average volume of 1.16M. On a monthly basis, the volatility of the stock is set at 6.61%, whereas on a weekly basis, it is put at 5.61%, with a gain of 13.15% over the past seven days. Furthermore, long-term investors anticipate a median target price of $12.42, showing growth from the present price of $4.13, which can serve as yet another indication of whether CRDF is worth investing in or should be passed over.
How Do You Analyze Cardiff Oncology Inc Shares?
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 8.68%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 42.26% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
